AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8532923 — intervention group
Group type: EXPERIMENTAL
Intervention: External high frequency oscillation around a negative baseline (EHFO‐NB)
Number of subjects: 20
Study 2006664 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics with or without methyldopa
Number of subjects: 822
Study 2006664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study 7005474 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 19
Study 7005474 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 19
Study 31625483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored dietary counselling using a computer-based algorithm
Number of subjects: 80
Study 31625483 — intervention group
Group type: COMPARATOR
Intervention: Generic dietary guidelines (Control)
Number of subjects: 80
Study 31501124 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic tablets containing Streptococcus salivarius M18 and Lactobacillus acidophilus with regular oral hygiene
Number of subjects: 50
Study 31501124 — intervention group
Group type: COMPARATOR
Intervention: Regular oral hygiene alone
Number of subjects: 50
Study 31501124 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic tablets
Number of subjects: 50
Study 29669596 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5-μg sublingual tablets of misoprostol
Number of subjects: 140
Study 29669596 — intervention group
Group type: COMPARATOR
Intervention: Placebo sublingual tablets and 25-μg vaginal tablets of misoprostol
Number of subjects: 140
Study 27725525 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation technique using quantitative coronary angiography (QCA)
Number of subjects: 87
Study 27725525 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation technique using optical coherence tomography (OCT)
Number of subjects: 87
Study 27725525 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque morphology
Number of subjects: 87
Study 27725525 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-artery ratio
Number of subjects: 87
Study 24698648 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard stretching exercise intervention (n=40)
Number of subjects: 80
Study 24698648 — intervention group
Group type: COMPARATOR
Intervention: Enhanced stretching exercise intervention (n=40)
Number of subjects: 80
Study 22182263 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults in the Making (AIM) program
Number of subjects: 347
Study 22182263 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 347
Study 21076354 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubbed and rinsed lenses (60s at visit 1, 20s at visit 2)
Number of subjects: 20
Study 21076354 — intervention group
Group type: COMPARATOR
Intervention: Control lenses (directly from blister pack to storage case)
Number of subjects: 20
Study 21076354 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort scores for both test and control lenses
Number of subjects: 20
Study 17716389 — intervention group
Group type: EXPERIMENTAL
Intervention: i-NPH patients
Number of subjects: 19
Study 15980034 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline diabetes
Number of subjects: 2040
Study 15980034 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes without microvascular disease
Number of subjects: 2040
Study 15980034 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes with microvascular disease
Number of subjects: 2040
Study 15980034 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher glucose levels
Number of subjects: 2040
Study 15980034 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with microvascular complications and glucose level <7.7 mmol/L
Number of subjects: 2040
Study 12164728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependence Scale scores
Number of subjects: 230
Study 12164728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependence level
Number of subjects: 230
Study 12164728 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in patient dependence
Number of subjects: 230
Study 10578025 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (Group A)
Number of subjects: 45
Study 10578025 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (Group B)
Number of subjects: 45
Study 10578025 — intervention group
Group type: COMPARATOR
Intervention: Both enteral and parenteral nutrition (Group C)
Number of subjects: 45
Study 7485307 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (50 micrograms intravaginally)
Number of subjects: 103
Study 7485307 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 (0.5 mg intracervically)
Number of subjects: 103
Study 7485307 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 103
Study 7485307 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2
Number of subjects: 103
Study 1691900 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-molecular-weight hydroxyethyl starch solution
Number of subjects: 0
Study 1691900 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight hydroxyethyl starch solution
Number of subjects: 0
Study 374194 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral BCG vaccine
Number of subjects: 48
Study 374194 — intervention group
Group type: COMPARATOR
Intervention: Control preparation
Number of subjects: 48
Study 31845273 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% PP and 40% sawdust
Number of subjects: 12
Study 31845273 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% PP and 30% sawdust
Number of subjects: 12
Study 31845273 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% PP and 20% sawdust
Number of subjects: 12
Study 31845273 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% PP and 10% sawdust
Number of subjects: 12
Study 31866800 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 40
Study 31866800 — intervention group
Group type: COMPARATOR
Intervention: Gd-DTPA
Number of subjects: 40
Study 27885763 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation awareness training (MAT)
Number of subjects: 74
Study 27885763 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behaviour theory for groups (active control)
Number of subjects: 74
Study 25542393 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit artery occluded (TIMI 0 to 1)
Number of subjects: 1319
Study 25542393 — intervention group
Group type: COMPARATOR
Intervention: Culprit artery patent (TIMI 2 to 3)
Number of subjects: 1319
Study 23307395 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Care
Number of subjects: 904
Study 23307395 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 904
Study 21437363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt bread (1.4% salt)
Number of subjects: 58
Study 21437363 — intervention group
Group type: COMPARATOR
Intervention: Ordinary bread (2% salt)
Number of subjects: 58
Study 18035430 — intervention group
Group type: EXPERIMENTAL
Intervention: Convenience sample (n=142)
Number of subjects: 299
Study 18035430 — intervention group
Group type: EXPERIMENTAL
Intervention: Snowball sample (n=60)
Number of subjects: 299
Study 18035430 — intervention group
Group type: COMPARATOR
Intervention: Random sample (n=97)
Number of subjects: 299
Study 16418306 — intervention group
Group type: EXPERIMENTAL
Intervention: Male infants
Number of subjects: 76
Study 16418306 — intervention group
Group type: COMPARATOR
Intervention: Female infants
Number of subjects: 76
Study 12594686 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Fr catheters
Number of subjects: 1114
Study 10733114 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg IV every 6 hours)
Number of subjects: 134
Study 10733114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 10733114 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 134
Study 8835890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (20 patients)
Number of subjects: 80
Study 8835890 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 patients)
Number of subjects: 80
Study 8835890 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 patients)
Number of subjects: 80
Study 8835890 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-reducing therapy (all drugs)
Number of subjects: 80
Study 1575589 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg, intramuscular injection)
Number of subjects: 8
Study 1575589 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intramuscular injection)
Number of subjects: 8
Study 3909329 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam, 2.0 g every 8‐12 hr
Number of subjects: 21
Study 3909329 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 21
Study 3909329 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 21
Study 30597578 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery exposure to alcohol-related cues
Number of subjects: 0
Study 30597578 — intervention group
Group type: COMPARATOR
Intervention: Binge and heavy drinkers
Number of subjects: 0
Study 29370583 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 109
Study 29370583 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in ER-positive or luminal tumours
Number of subjects: 109
Study 29370583 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-set enrichment analysis
Number of subjects: 109
Study 27079717 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 39
Study 27079717 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 39
Study 26135893 — intervention group
Group type: EXPERIMENTAL
Intervention: Caprylic acid (CA) 0.7%
Number of subjects: 2
Study 26135893 — intervention group
Group type: EXPERIMENTAL
Intervention: Caprylic acid (CA) 1.0%
Number of subjects: 2
Study 26135893 — intervention group
Group type: COMPARATOR
Intervention: Control (0% CA)
Number of subjects: 2
Study 26135893 — intervention group
Group type: EXPERIMENTAL
Intervention: Caprylic acid (CA) (0.7% and 1%)
Number of subjects: 2
Study 26135893 — intervention group
Group type: EXPERIMENTAL
Intervention: Caprylic acid (CA)
Number of subjects: 2
Study 22990330 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg almorexant once daily for 9 days
Number of subjects: 14
Study 21281434 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN α‐2a plus ribavirin
Number of subjects: 217
Study 21281434 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN α‐2b plus ribavirin
Number of subjects: 217
Study 20183662 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysfunctional Attitudes Scale
Number of subjects: 422
Study 20183662 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlated 2‐factor model (perfectionism and need for social approval)
Number of subjects: 422
Study 16967682 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal ligation of the inferior thyroid arteries during bilateral subtotal thyroidectomy
Number of subjects: 98
Study 16967682 — intervention group
Group type: COMPARATOR
Intervention: No truncal ligation of the inferior thyroid arteries during bilateral subtotal thyroidectomy
Number of subjects: 98
Study 14677608 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100 ppm fluoride dentifrice
Number of subjects: 644
Study 14677608 — intervention group
Group type: EXPERIMENTAL
Intervention: 2800 ppm fluoride dentifrice
Number of subjects: 644
Study 14677608 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries scores on occlusal surfaces
Number of subjects: 644
Study 14677608 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 644
Study 11190775 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dimetindene maleate spray (Fenistil Nasal Dosierspray)
Number of subjects: 36
Study 11190775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9345680 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical tests used in physical examination of the neck
Number of subjects: 50
Study 8063496 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-touch technique for tympanostomy tube insertion
Number of subjects: 66
Study 8063496 — intervention group
Group type: COMPARATOR
Intervention: Touched control technique for tympanostomy tube insertion
Number of subjects: 66
Study 3057674 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prazosin (2 mg twice daily) for three weeks
Number of subjects: 24
Study 30044295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal tip lifting group
Number of subjects: 86
Study 30044295 — intervention group
Group type: COMPARATOR
Intervention: Neutral group
Number of subjects: 86
Study 30044295 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower pathway
Number of subjects: 86
Study 30044295 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper pathway
Number of subjects: 86
Study 28167721 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized letters and e-mails with information about potential savings on insurance premiums
Number of subjects: 0
Study 28167721 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic communications emphasizing the possibility of saving
Number of subjects: 0
Study 26376765 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of mupirocin (three times a day)
Number of subjects: 4
Study 26376765 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of mupirocin (once a day)
Number of subjects: 4
Study 26376765 — intervention group
Group type: COMPARATOR
Intervention: Single povidone iodine (PVP-I)
Number of subjects: 4
Study 24354929 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 69
Study 24354929 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily) plus Ezetimibe (10 mg daily)
Number of subjects: 69
Study 24354929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 22733462 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based renal sympathetic denervation (RD)
Number of subjects: 100
Study 22733462 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 20302811 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management (tonsillectomy/adeno-tonsillectomy)
Number of subjects: 729
Study 20302811 — intervention group
Group type: COMPARATOR
Intervention: Medical management (non-surgical conventional treatment)
Number of subjects: 729
Study 18400276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardscan
Number of subjects: 50
Study 18400276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladderscan
Number of subjects: 50
Study 18400276 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐US system
Number of subjects: 50
Study 18400276 — intervention group
Group type: COMPARATOR
Intervention: Voided volume
Number of subjects: 50
Study 18400276 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods (Bardscan, Bladderscan, 3D‐US)
Number of subjects: 50
Study 15735443 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir + stavudine + lamivudine (group 1)
Number of subjects: 141
Study 15735443 — intervention group
Group type: COMPARATOR
Intervention: Indinavir + stavudine + nevirapine (group 2)
Number of subjects: 141
Study 15735443 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral-naive patients
Number of subjects: 141
Study 15735443 — intervention group
Group type: COMPARATOR
Intervention: Pretreated patients
Number of subjects: 141
Study 12207597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol short contact therapy
Number of subjects: 216
Study 12207597 — intervention group
Group type: COMPARATOR
Intervention: UVB phototherapy
Number of subjects: 216
Study 12207597 — intervention group
Group type: COMPARATOR
Intervention: Inpatient dithranol treatment
Number of subjects: 216
Study 10476894 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily for one week with bioabsorbable membrane
Number of subjects: 24
Study 10476894 — intervention group
Group type: COMPARATOR
Intervention: Polylactide bioabsorbable membrane alone
Number of subjects: 24
Study 9412747 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% P4S3 in pet.
Number of subjects: 0
Study 9412747 — intervention group
Group type: COMPARATOR
Intervention: 1% P4S3 in pet.
Number of subjects: 0
Study 8229546 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed-release 5-ASA (50 mg/kg/day, maximum 3 g/day) for 8 weeks
Number of subjects: 14
Study 8229546 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 14
Study 2431074 — intervention group
Group type: EXPERIMENTAL
Intervention: vidarabine monophosphate (ara-AMP)
Number of subjects: 27
Study 2431074 — intervention group
Group type: COMPARATOR
Intervention: acyclovir (ACV)
Number of subjects: 27
Study 2431074 — intervention group
Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 27
Study 30464435 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 0
Study 30464435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26062916 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine Ingestion (6 mg/kg BW)
Number of subjects: 38
Study 26062916 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine Rinse (1.14%)
Number of subjects: 38
Study 26062916 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine Ingestion + Rinse
Number of subjects: 38
Study 26062916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 25274568 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter drink
Number of subjects: 0
Study 25274568 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 0
Study 23588439 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (S; n = 19)
Number of subjects: 66
Study 23588439 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E; n = 25)
Number of subjects: 66
Study 23588439 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of endurance and strength training (SE; n = 22)
Number of subjects: 66
Study 23588439 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity group (PA; n = 18)
Number of subjects: 66
Study 20378504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab combined with FOLFOX6 (leucovorin 5‐fluorouracil/oxaliplatin); cetuximab at a loading dose of 400 mg/m2 followed by 250 mg/m2 weekly and FOLFOX6 regimen every 2 weeks consisting of oxaliplatin 85 mg/m2, LV 400 mg/m2, and 5‐FU bolus 400 mg/m2 followed by 5‐FU continuous infusion 2400 mg/m2 over 46 hours.
Number of subjects: 82
Study 18564988 — intervention group
Group type: EXPERIMENTAL
Intervention: Torque Teno Virus (TTV) infection
Number of subjects: 25
Study 18564988 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients on calcineurin inhibitors (CNI) and azathioprine or mycophenolate mofetil
Number of subjects: 25
Study 18564988 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver cirrhosis patients
Number of subjects: 25
Study 17037284 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (ACE inhibitors, beta-antagonists, diuretics)
Number of subjects: 0
Study 17037284 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aspirin (300 mg/day)
Number of subjects: 0
Study 17037284 — intervention group
Group type: COMPARATOR
Intervention: Low dose aspirin (not specified)
Number of subjects: 0
Study 12428175 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil-based cheese
Number of subjects: 31
Study 12428175 — intervention group
Group type: COMPARATOR
Intervention: Milk-fat-based control cheese
Number of subjects: 31
Study 10349919 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA) with bupivacaine 0.125% and fentanyl 5 microg/ml
Number of subjects: 22
Study 10349919 — intervention group
Group type: COMPARATOR
Intervention: Lumbar Epidural Analgesia (LEA) with morphine 0.2 microg/ml
Number of subjects: 22
Study 7575771 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg once daily, increased to target levels of LDL cholesterol between 2.3 mmol/l (90 mg/dl) and 3.6 mmol/l (140 mg/dl)
Number of subjects: 168
Study 7575771 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (various dosages: 40 mg, 20 mg, 10 mg, 5 mg)
Number of subjects: 168
Study 7575771 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 168
Study 7870911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (2 mg/kg)
Number of subjects: 13
Study 7870911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3710668 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise tests
Number of subjects: 18
Study 30278936 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Apgar Score (SAS) risk categories (low: SAS 7-10, intermediate: SAS 5-6, high: SAS 0-4)
Number of subjects: 405
Study 30278936 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Apgar Score (SAS)
Number of subjects: 405
Study 25348683 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial pancreas (AP) system
Number of subjects: 16
Study 25348683 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 16
Study 24474396 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive cell therapy with TIL and high-dose aldesleukin after 12 Gy TBI
Number of subjects: 0
Study 21917306 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery (PDS)
Number of subjects: 316
Study 21917306 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 316
Study 20538634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous bevacizumab (1.25 mg, three loading injections at six week intervals)
Number of subjects: 131
Study 20538634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous bevacizumab
Number of subjects: 131
Study 20538634 — intervention group
Group type: COMPARATOR
Intervention: Standard care (pegaptanib sodium, verteporfin, sham)
Number of subjects: 131
Study 18575048 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (ropivacaine 0.2% 10 ml, followed by an infusion of 5 ml/h for 96 hours)
Number of subjects: 188